Brokerages Set Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PT at $28.00

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned a consensus rating of “Reduce” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $28.00.

Several brokerages have recently commented on FMS. The Goldman Sachs Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Truist Financial set a $28.00 target price on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.8%

FMS opened at $24.64 on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.94 and a 12-month high of $30.46. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00. The stock has a market capitalization of $14.28 billion, a PE ratio of 17.99, a P/E/G ratio of 0.77 and a beta of 0.90. The firm’s fifty day moving average price is $23.28 and its 200 day moving average price is $24.48.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently bought and sold shares of FMS. US Bancorp DE boosted its stake in Fresenius Medical Care AG & Co. KGaA by 225.5% during the 2nd quarter. US Bancorp DE now owns 75,660 shares of the company’s stock valued at $2,162,000 after purchasing an additional 52,418 shares during the period. Todd Asset Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% during the third quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after buying an additional 64,311 shares during the last quarter. ABC Arbitrage SA boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 18.2% during the second quarter. ABC Arbitrage SA now owns 229,375 shares of the company’s stock worth $6,553,000 after buying an additional 35,314 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 26.8% during the second quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock worth $10,684,000 after buying an additional 78,956 shares during the period. Finally, Trustmark Bank Trust Department bought a new position in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth approximately $1,027,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.